TD Asset Management
RAPP

TD Asset Management’s Rapport Therapeutics RAPP Stock Holding History

TD Asset Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.83M Sell
91,878
-7,200
-7% -$265K ﹤0.01% 865
2026
Q1 		$3.1M Sell
99,078
-16,112
-14% -$453K ﹤0.01% 878
2025
Q4 		$3.49M Sell
115,190
-21,824
-16% -$604K ﹤0.01% 865
2025
Q3 		$4.07M Sell
137,014
-59,856
-30% -$1.07M ﹤0.01% 822
2025
Q2 		$2.24M Buy
196,870
+34,052
+21% +$361K ﹤0.01% 902
2025
Q1 		$1.63M Sell
162,818
-15,088
-8% -$196K ﹤0.01% 1011
2024
Q4 		$3.16M Buy
177,906
+115,708
+186% +$2.56M ﹤0.01% 886
2024
Q3 		$1.33M Sell
62,198
-39,324
-39% -$845K ﹤0.01% 1142
2024
Q2 		$2.36M Buy
+101,522
New +$2.35M ﹤0.01% 944

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TD Asset Management's RAPP Position: Q2 2026 in Review

TD Asset Management reduced its Rapport Therapeutics (RAPP) stake by 7.3% in Q2 2026, selling an estimated $265K and leaving 91,878 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #865.

TD Asset Management first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. The position peaked at $4.07M in Q3 2025. 103 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • TD Asset Management held 91,878 shares of Rapport Therapeutics worth $3.83M as of Q2 2026.
  • TD Asset Management sold 7,200 Rapport Therapeutics shares in Q2 2026, an estimated $265K.
  • Rapport Therapeutics made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #865 holding.
  • TD Asset Management first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • TD Asset Management's Rapport Therapeutics position peaked at $4.07M in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.